PrEP 2 Live

Prepped to Live, Once a Day!
  • Facebook - White Circle
  • Pinterest - White Circle
  • Instagram - White Circle

Our 2017-2018 Campaign

Undertaking this effort was conceived and directed by Community Connector facilitator of Arkansas RAPPS, Mr. Cornelius Mabin. Through his dynamic creativity and resourcefulness the project moved swiftly from inception to launch in late spring 2017. The end result has delivered a striking imagery, messaging and innovative deployment strategies to increase PrEP awareness and access to this prevention method.


Our Story, OurMission

"One new HIV infection in Arkansas is one too many."

The Arkansas HIV Planning Group has been steadfast in our collaborative partnership with the Arkansas Department of Health's Infectious Disease Branch in assessing the prevention and intervention needs of addressing HIV in Arkansas. With advances and breakthrough's moving us forward with fourth generation we are also supporting the use of PrEP (pre-exposure prophylaxis) is a highly effective HIV prevention method approved in the US by the FDA in July 2012.  AHPG supports the innovators and champions of expanded HIV prevention methods and the rapid scale up of wide PrEP implementation by posting information, links and valuable resources to be accessed all Arkansans.


The Resources

6 Facts to Know About PreP

Download a printable pdf version here.

  • PrEP works if you take it.
    Across populations, geography and route of exposure the data all point in the same direction—TDF-based PrEP works if you take it.

  • It's safe.
    There were no major adverse events observed in any of the trials. Some mild side effects were reported, the majority of which went away over time.

  • Adherence is essential.
    Each of the trials that found benefit also found that people who had high levels of adherence had high levels of protection. Lower adherence was associated with low or no protection.

  • It works for both men and women.
    PrEP is highly protective in both men and women, but women may need to be more adherent to reap maximum benefit (as the drug concentrates differently in the vagina as compared to the rectum).

  • People who can benefit most from PrEP can — and do — take it.
    Early implementation projects show that those who are at highest risk of exposure can also be highly adherent to PrEP.

  • Resistance is rare.
    Individual cases of HIV drug resistance (which could emerge if a person acquired HIV while on PrEP and went on taking the single drug during the time before diagnosis) have been observed in trials to date. These appear to have occurred in participants who were HIV-positive and in the “window period” of early infection when they began taking PrEP. These individuals tested HIV-negative on the trials’ screening tests. This reinforces the importance of regular testing for anyone initiating or taking PrEP.


We are here to serve all of Arkansas!


Contact Us

Arkansas HIV Planning Group

P.O. Box 166061

Little Rock, Arkansas 72216
Tel: 501.349.7777


Success! Message received.